Beta-adrenergic blocking agent in cardiovascular disease: focus on metoprolol

Abstract

This article presents the data on the therapeutic efficacy ofbeta-adrenergic blocking agentsin ischemic heart disease, chronic heart failure (CHF), arterial hypertension. We analyzed the basic pharmacological mechanism of action of these drugs class. The comparison of pharmacodynamic and pharmacokinetic characteristics of metoprolol succinate retard with other beta-adrenoreceptor-blocking agents showed metoprolol succinate advantage over the short-term drugs for treatment of CHF. According to the results of randomised clinical trialswe determined high therapeutic efficacy and safety of metoprolol succinate retard.

Keywords

• beta-adrenergic blocking agent
• metoprololsuccinate
• ischemic heart disease
• chronic cardiac failure
• arterial hypertension